



# 2025 PRESS KIT



TOGETHER, BEYOND ANIMAL HEALTH





# Contents

- 4 Ceva, a success story
- 5 Ceva at a glance
- 6 Key dates leading to success
- 7 Ceva, an innovative company
- 8 Zoom on the innovative Ceva facilities
- 9 Ceva HQ: a new centre for excellence
- 10 Species focus
- 12 The power of the #OneCeva community
- 14 Ceva, a One Health holistic approach
- 16 One Planet, Ceva's vision for the future



# Ceva, a success story

Ceva Animal Health (Ceva) is a French independent animal health company majority-owned by its employees. Led by experienced veterinarians, Ceva's mission is to provide innovative health solutions for all animals, to ensure the highest level of care and well-being.

The company is now the 5th largest player in the world and is present in 110 countries.

Ceva's portfolio includes vaccines, animal welfare products, pharmaceutical and biopharmaceutical solutions for farm and companion animals, and equipment and services to provide the best experience for customers.

Since its creation in 1999 and its first LBO, it has been in Ceva's DNA to be and to remain a free, independent firm. Its success is based on its ability to innovate and its commitment to contributing to the future of our planet.

Starting in 2007, the company has been supported by long-term, carefully selected, financial partners who share their values, vision and sense of purpose. These partners' trust and support are essential for Ceva to achieve its growth objectives and ensure the company's independent future in the long term.

For over 25 years, Ceva has been advocating for prevention through vaccination. This is why the company have heavily invested in preventive medicine, to prepare for future pandemics, among other things. This prevention-first methodology has been vital

for our impact on the animal health sector and in the development of revolutionary vaccines.

In 2025, Ceva strengthened its position in the animal health sector through a strategic capital restructuring that balanced management independence with new investment opportunities. The company's innovative approach attracted a diverse range of investors, combining loyal "Friends of Ceva" partners with prominent global investment firms. This carefully crafted shareholding structure not only demonstrates investor confidence in Ceva's future but also reinforces the company's dedication to advancing animal health solutions and environmental sustainability.

Three fundamental pillars underpin Ceva's purpose:

- **#OneCeva** by bringing together the people who breathe life into Ceva every day.
- **#OneHealth** by preserving the health of all, from animals to humans to our planet through an integrated health approach.
- **#OnePlanet** by supporting initiatives aimed at protecting the health of our environment in general and of wild animals in particular.

#Ceva

#OneHealth

#OnePlanet



# CEVA AT A GLANCE



**5<sup>th</sup>** largest player in the global market and present in **110 countries**



Ceva has increased its size by **x14** since its creation in late **1999**



**7000+** employees in **47 countries**



**32 production sites** around the world



2024 revenues: **1,77bn**



**21** established R&D sites

## A GLOBAL INDUSTRIAL FOOTPRINT



### PHARMACY

Europe: 6 sites  
Eastern Europe,  
Middle East,  
and Africa:  
4 sites  
Latin America: 3 sites  
Asia-Pacific: 2 sites

### BIOLOGY

Europe: 6 sites  
North America: 6 sites  
Latin America: 2 sites  
China: 2 sites

### BIOTECHNOLOGY

Europe: 1 site  
Latin America:  
1 site

### EQUIPMENT & SERVICES

Europe: 2 sites

# KEY DATES LEADING TO SUCCESS

1999

Ceva Animal Health was formed when management conducted its first LMBO (leveraged management buyout).

2005

The acquisition of Biomune, producer of avian vaccines, permitted a vital return to the key US market. The portfolio included new technology vaccines - this was the birth of the Vectormune product line for poultry.

2007

Ceva management and its employees became majority shareholders during the third financial round.

2010

In its first decade, Ceva became the fastest-growing animal health company. Acquisition of Vectra, a key solution against parasites, in the United States.

2011

Ceva Huadu, dedicated to avian vaccines, became the company's first joint venture established in China.

2013

The acquisition of Sogeval allowed Ceva to become a leader in France and to enter the pet dermatology market with the Douxo product line.

2014

Capital restructuring to support the launch of the "Ambition 2020" business plan. Temasek, CDC, Sofiproteol and Merieux Development joined as investors alongside "Friends of Ceva" to help accelerate the company's growth.

2017

Ceva entered the top 5 on the Brazilian market with the acquisition of Circovac and the integration of Hertape-Inova. Creation of Ceva Ebvac, a new joint venture in China dedicated to swine vaccines.

2019

Creation of a global swine innovation with the acquisition of IDT's veterinary business.

2020

Ceva achieved its "Ambition 2020" growth targets and successfully refinanced the company to help ensure its future growth. Téthys, PSP, Mitsui, Klocke and Continental Grain became shareholders.

2022

Ceva continued its expansion, first in Asia with the creation of a joint venture with Mitsui & Co., Ltd, and then in South America with the acquisition in Argentina of a biotech campus and a company, Zoovet. Ceva also expanded its oral rabies vaccines portfolio with the acquisition of a Canadian company, Artemis Technologies, Inc.

2024

Ceva acquired Scout Bio, a pioneer in biotechnology focused on cutting-edge therapies for pets. A significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.

Ceva Animal Health partners with Touchlight to use their dbDNA technology for developing animal health products. The collaboration aims to create new DNA vaccines and therapeutics, leveraging Ceva's development expertise and Touchlight's rapid, high-purity DNA production.

2025

Ceva restructured its capital, maintaining management control while adding Mérieux Institute and ARCHIMED as new investors. With €1.77 billion in revenue and 7,000 employees across 47 countries, Ceva continues its focus on innovative animal health solutions and preventive medicine.

# Ceva, an innovative company



Ceva's solutions deliver transformative approaches that are reshaping animal health and advancing sustainability, with significant investment focused on preventative medicine. This preventative strategy aims to stop diseases before they emerge, rather than treating them after the fact.

Ceva's innovation comes from its dedication towards internal R&D projects such as its revolutionary mRNA Platform. This technological platform is designed to produce a rapid response to emerging viruses, enabling the adaptation and development of new vaccines that overcome species barriers. The company's emphasis on preventative medicine is reflected in its substantial investment in vaccine research and development, which forms a cornerstone of its proactive approach to animal health.

With 21 R&D centres worldwide, Ceva is one of the most innovative animal health companies in vaccine technologies and one of the leading players on a global scale:

- Ceva is the first and only company to have developed an mRNA platform for animals in less than three years. These are created in a laboratory to teach our cells how to make a protein, or even just a piece of a protein, that triggers an immune response inside bodies.
- Ceva is the historical world leader in vector vaccines for poultry and remains the world leader in broiler vaccination and #1 in hatchery vaccination.
- Ceva also has global expertise in autogenous vaccines, to bring solutions in less than 100 days.
- Ceva covers 6 vaccine technologies: from simple inactivated to live and vectorized vaccines or immune complex and subunit vaccines.

- Ceva has also developed and manufactures several oral rabies vaccines, playing a crucial role in campaigns focused on the successful eradication of rabies worldwide.
- Biogenovac, Ceva's new genomics laboratory in France, focuses on developing next-generation vaccines using high-throughput sequencing and bioinformatics to identify, analyze, and combat emerging animal diseases through advanced nucleotide vaccine technology.

Ceva Biotechnology Campus (CBC), located in Philadelphia, formally known as Scout Bio, which was acquired in 2024, is at the forefront of developing groundbreaking biotherapeutic products. CBC is propelling innovation in the animal health sector. Through quality clinical health trials, ground-breaking product development and the creation of disruptive technologies, Ceva is expanding the possibilities of animal health. Ceva is also maintaining close relationships with the world-renowned Gene Therapy Programme at the University of Pennsylvania to expand innovation horizons even further.

Ceva has **21** dedicated R&D centres.

The company invests **10%** of its revenue into R&D projects each year.

Ceva allocates **40 %** of its R&D budget to vaccine development, **25 %** to biopharmaceuticals, and **35 %** to pharmaceutical products.



# Zoom

## on the innovative Ceva facilities



### **Ceva Biogenovac** (France)

Ceva Animal Health's new Biogenovac laboratory in Beaucouzé, France, is a cutting-edge genomics research facility focused on developing next-generation vaccines for animal diseases. The facility combines high-throughput sequencing with advanced bioinformatics to identify pathogens, analyse genetic sequences, and create nucleotide vaccines. Its centralised data analysis system enables researchers to develop and adapt vaccines quickly in response to emerging animal health threats, particularly in Western Europe. This partially government-funded facility represents a significant advancement in Ceva's research and development capabilities.

### **New vaccine manufacturing plant in Monor** (Hungary)

The construction of a new vaccine manufacturing plant in Hungary is Ceva's latest commitment to providing a new local production hub within Europe. The €75 million development is scheduled to start operations at the end of 2026 and will establish a 7,000m<sup>2</sup> plant in Monor, Hungary, with

the most advanced technologies to produce 8 billion doses annually. This facility will see Ceva produce fermentation-based multicomponent inactivated vaccines for animals that will further expand the company's global vaccine production capacity.

### **Ceva Montpon-Ménestérol** (France)

Ceva's brand-new European logistics centre in Montpon-Ménestérol is located 40 km from the company's historic headquarters and one of its major campuses in Libourne, France. This platform has been designed to store and ship Ceva's products developed in Europe as its first European logistics site capable of serving up to 130 countries.

Equipped with the latest digital and automation technologies, this new centre embodies the future of distribution. The 12,000m<sup>2</sup> dedicated to storage cells is equipped with a Warehouse Management System (WMS) that optimizes all logistics flows (20,000 pallets stored for 2,800 listed products), from reception to shipment, and includes autonomous

tri-directional carts to facilitate storage and order preparation. These innovations ensure maximum efficiency, reducing lead times and optimizing the supply chain.







# Ceva Headquarters: a new centre for excellence

**Ceva has built a distinctive new circular-shaped headquarters in Libourne, Gironde, France. The building represents a significant architectural statement, designed to harmonise with its natural surroundings while incorporating advanced environmental features, including geothermal energy, solar panels, natural lighting, and acoustic optimisation.**

The project embodies Ceva's three core dimensions: #OneCeva (working together with passion), #OneHealth (developing innovative solutions for all animals), and #OnePlanet (promoting biodiversity and corporate responsibility).

The new Ceva headquarters features a distinctive circular design that harmoniously integrates with its natural surroundings in Libourne, France. The building has a unique ring-shaped structure with an open central courtyard, surrounded by modern architectural elements including wooden columns and large glass surfaces. The circle represents the world, with the square central courtyard representing structure. The building's shape allows it to be both modern and

discreet while maintaining a strong connection to the natural environment. The building's design emerged from collaborative workshops involving future occupants, ensuring the space meets diverse working styles and generational needs. The unique circular architecture integrates seamlessly into the natural landscape, featuring sustainable design elements, collaborative workspaces with modern amenities, and intergenerational workspace considerations.

The headquarters' location choice, away from major cities and in a natural setting, demonstrates Ceva's dedication to environmental responsibility and future generations. The location was also chosen as a way to stay in the heart of the territory and remain close to the clients. While the interior spaces have been co-created to reflect employee needs and working styles.

This project represents Ceva's commitment to remaining true to its regional roots while building a modern, sustainable workplace that reflects its position as the world's fifth-largest animal health company, creating an environment that promotes both productivity and well-being.





## POULTRY

Over the past twenty years, Ceva has emerged as a pioneering force in poultry vaccination, particularly in hatchery-level interventions. The company provides veterinarians and producers with digital tools for comprehensive audits and training. Additionally, innovations like Genesys, a compact system for gender sorting day-old broilers – designed exclusively to rear males and females separately, ensuring optimal care for each – have transformed hatchery efficiency worldwide. With this momentum, Ceva aims to achieve global leadership in poultry medicine by 2025 and cement its position as the undisputed industry leader by 2035.

## SWINE

The Ceva Swine team is expanding its focus from respiratory disease prevention to reproduction, offering comprehensive solutions that enhance pig health and farm sustainability. At the forefront is the EASI smart needle device, which revolutionizes piglet treatment through integrated software analytics and RFID tracking. With these innovations, Ceva aims to establish itself as a leader in swine biology and specialized pharmaceutical segments.





## COMPANION ANIMALS

Ceva understands that fostering harmonious relationships between owners and their pets is of key importance. To support this, Ceva invests in three strategic areas: behaviour, parasitology and vet specialties. In each of the strategic areas, Ceva teams have developed effective solutions that are easy to implement, thanks to comprehensive support programmes available online. Ceva is a recognised player in the companion animals sector, and continues to strengthen its position in underpenetrated markets, particularly regarding pet safety.

## RUMINANTS

The Ceva Ruminants team is dedicated to advancing sustainable ruminant production by offering customized solutions that protect and care for animals throughout their lives. We provide a comprehensive range of products, including vaccines, anti-infectives, reproductive aids, and parasiticides, all designed to enhance animal health and welfare. Additionally, Ceva is committed to creating innovative diagnostic tools to assist veterinarians in diagnosing and managing ruminant diseases.





# The power of the #OneCeva community

Ceva is a purpose-driven company, crafting a vibrant and diverse ecosystem.

Ceva's central business purpose is "together, our passionate people drive innovative health solutions for all animals, contributing to the future of our diverse planet". This is where the first central pillar #OneCeva comes into play.

The dynamic Ceva community, comprising of more than 7,000 employees spread across 47 countries, is the heartbeat of the company's success. All together, we strive every day to align Ceva's activities with the company's purpose. Through shared experiences and collaborative efforts, we truly set it apart.

The diversity within Ceva's team is a vital strength that enables the company to tackle the complex challenges of animal health. From research and development to veterinary care, production, and distribution, employees bring their unique know-how and total commitment to improving the lives of animals, people, and the planet for a more resilient and sustainable future.

With all this in mind, Ceva has launched its new Employer Value Proposition (EVP) with a clear statement that reflects the organisation's ethos and its commitment to employees. The EVP outlines the values, recognition, support, and culture the company offers, aiming to empower employees to perform at their best and unlock their full potential. At its heart, the EVP serves as a promise to the workforce, aligning their experiences with the company's core mission and values.

**The three pillars of Ceva's EVP aim to create an organisation which is:**



## INSPIRING

To act  
with purpose

At Ceva, passion is more than just a word, it is a driving force that animates the entire team globally. This bold vision acts as the inspiration to build a future together that protects all animals, and beyond that also preserves human health and the rich biodiversity of our planet.

Each employee embodies a deep commitment and a strong sense of responsibility, bringing powerful meaning into our daily actions. This commitment is genuine and unwavering, always guided by the desire and passion to better serve both clients and the company's core beliefs.



## IMPACTFUL

To make  
a difference

At Ceva, the entrepreneurial spirit is much more than just a stated value; it is a tangible reality, perceived and experienced by all employees. It is a key component of the corporate culture. In Ceva's dynamic, international ecosystem, change is fulfilled through the ability to transform these aspirations and ideas into concrete achievements and innovations that shape the future of animal health and beyond.

Working at Ceva means embracing a mindset where every challenge becomes an opportunity to innovate and excel. Ceva's strength lies in the unique synergy between creativity, agility and pragmatism of its teams, coupled with their audacity to challenge the status quo.



## TRANSFORMATIVE

To grow  
together

Ceva has created a dynamic environment where every experience is an opportunity to learn and progress. This is embodied through the "test & learn" philosophy and commitment to continuous improvement at the core of daily operations.

Ceva provides a fertile ground for experimentation, where employees can dare to step out of their comfort zone and shape their own professional trajectory. This collaborative approach amplifies development opportunities.

Ceva boasts a close-knit community, where trust, mutual support and team spirit are the pillars of company growth.





## Ceva, a One Health holistic approach

Ceva has always been a One Health company. We are committed to preserving the delicate balance between animals, humans, and the environment to make a positive contribution to the future of the planet, for the benefit of all.

With the #OneHealth pillar, Ceva strives to be more than just a company committed to animal health, but a #OneHealth company that plays an essential role in preserving the health of all: from animals to humans to our planet.

**The One Health concept covers issues such as the fight against zoonoses and antimicrobial resistance, food safety and security but also the essential link between humans and animals or the support to all forms of sustainable agriculture – large and small scale.**

For over 25 years, Ceva has advocated for prevention through vaccination, heavily investing in preventive medicine, among other things, to combat zoonotic diseases and prepare for future pandemics.

This preventive approach is fundamental as the World Health Organization estimates that 70% of new emerging diseases in humans are of animal origin; it also helps reduce the prescription of antibiotics, thus effectively combating antimicrobial resistance.

It is, therefore, Ceva's duty, as a veterinary company, to prevent these zoonotic diseases. In this regard, Ceva allocates 40 % of its R&D budget to vaccine development, 25 % to biopharmaceuticals, and 35 % to pharmaceutical products. This prevention-first methodology has been vital for their impact on the animal health sector and in the development of revolutionary vaccines.

Ceva's preventive medicine mission centres on developing innovative health solutions to protect animal well-being before diseases take hold. Their portfolio of preventive medicines and vaccines is designed to ensure the highest level of animal care while supporting global health security and sustainable livestock production. This preventive approach is fundamental as it also helps reduce the prescription of antibiotics, thus effectively combating antimicrobial resistance.



Ceva understands the crucial importance of protecting our environment to ensure a sustainable future for all, reflected through #OnePlanet, Ceva's strong commitment to preserving the diversity of our planet.

Society expects businesses to play a role in resolving the major challenges facing our planet. Ceva takes its responsibilities and invests to make the company more sustainable and more resilient. In order to reduce its environmental footprint, the company strives

to reduce the impact of all of its activities, via ambitious programs: from waste production management, to emissions to air, water and soil, not to mention careful monitoring of water and energy consumption, and efforts to reduce CO<sub>2</sub> emissions.



## Wildlife Research Fund

Alongside globally recognized organisations, Ceva has been actively involved for many years in initiatives aimed at safeguarding biodiversity, while promoting sustainability inside Ceva and with customers and partners. The culmination of these beliefs is realised through the Ceva Wildlife Research Fund.

The Ceva Wildlife Research Fund is a one-of-a-kind endowment whose objective is to fund applied research projects. Its ultimate goal is to preserve the health of wild animals and contribute to the preservation of wild animal health.

*A comprehensive approach to biodiversity is nothing new for Ceva. But by creating this endowment fund, we wanted to create a separate structure to give this activity a home.*



The Ceva Wildlife Research Fund is a legal entity separate from Ceva Animal Health, chaired by Dr. Marc Prikazsky and led by Dr. Pierre-Marie Borne. A scientific committee made up of 7 persons meets at least once a year and is responsible for providing opinions on the various projects (selection, assessment and monitoring).

Funding supports applied research programs projects led by universities or renowned research centres, **the results of which will be quickly observable, with deadlines of three to five years maximum.**

The fund has already financed more than 12 programs that have become iconic for the research fund, such as vaccinating koalas, Australia's emblem, against chlamydia; monitoring Northern Gannets to help conserve the species; or supporting a pioneering PhD project to unlock the mysteries of the pangolin, among others.

### The 3 main missions

of the Ceva Wildlife Research Fund



Taking actions to preserve biodiversity



Fighting against zoonoses



Facilitating interactions between wildlife, livestock and humans

Currently, the Ceva Wildlife Research Fund project is funding and enabling around

## 12 different projects

Including...



Ensuring Australian koalas' survival as a species through testing and vaccination development.



Protecting at-risk birds at a Belgian wildlife park by funding a vaccination programme against Highly Pathogenic Avian Influenza (HPAI).



Fighting against the extinction of pangolins by funding research to successfully reintroduce the species into the wild.



Supporting the second phase of the BioBoundary project, which uses GPS collars on leopards to prevent them from preying on livestock and disrupting local farmers.



Developing and testing an adaptive approach to elephant management in South African reserves to create more effective population control strategies.





**Ceva Santé Animale**  
8, rue de Logrono  
33500 Libourne - France  
[www.ceva.com](http://www.ceva.com)

**Press contact:**  
**Emilie Barrail**  
[emilie.barrail@ceva.com](mailto:emilie.barrail@ceva.com)

**Join us**

